Charles River & Gyrolab^®

A global platform for bioanalytical excellence

Charles River's bioanalytical teams work with biologics of all types, including monoclonal antibodies, recombinant proteins, peptides, oligonucleotides, cell and gene therapies, and anti-drug antibodies, delivering GLP-compliant methods for both nonclinical and clinical sample analysis. Gyrolab is central to that capability.

The platform's automated workflow controls capture, sample addition, and detection with precision, removing analyst-to-analyst variability and ensuring consistent incubation across every run. The result is a stable, reproducible assay that holds performance over time and across sites.

 "Charles River remains committed to the identification and implementation of automated solutions across the entirety of the drug development journey. The walk-away benefits of the platform offer increased throughput and expedited results while requiring less sample volume. Availability of Gyrolab workstations throughout our global bioanalytical laboratories supports rapid implementation of methods and faster data delivery."

Vimal Patel, MBA, BS, Senior Director Global Lab Sciences, Charles River Laboratories 

Throughput and efficiency at CRO scale

For a CRO, speed and data quality are equally critical to sponsor delivery. Gyrolab generates up to 112 data points per hour and supports overnight runs with minimal hands-on time, substantially exceeding the throughput of conventional plate-based ELISA. Reduced sample volume requirements are a further advantage, particularly for sponsors working in programmes where sample availability is limited.

"The Gyrolab platform offers an efficient, semi-automated solution that delivers consistent, high-quality results while minimising sample volume — exactly what our sponsors need."

Thierry Basset, Laboratory Director, Charles River Laboratories Lyon

Validated methods across modalities

Charles River brings an extensive knowledge base in developing and validating sensitive, selective, and reproducible methods for biotherapeutics of any size. GLP-compliant validation, combined with Gyrolab's automated precision, supports reliable data delivery from early-stage studies through to clinical sample analysis.

"Gyrolab workstations are a valuable asset to Charles River for the development, validation, and execution of biomarker, pharmacokinetic, and immunogenicity assays for drug development."

Leslie Kuiper, MS, Associate Scientist, Charles River Laboratories